LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced the filing of its first-quarter 2026 Form 10-Q, highlighting continued advancement of its lead oncology candidate, LB-100. The company reported expansion of its ovarian cancer trial following favorable safety findings in combination with immunotherapy. LIXTE also cited continued growth at its recently acquired Liora Technologies Europe subsidiary as it pursues broader strategic expansion to strengthen its oncology pipeline and treatment development capabilities.
LB-100 is a first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, improving outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology—activation lethality—that is advancing a new treatment paradigm. The company holds a comprehensive patent portfolio covering its novel approach, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
The expansion of the ovarian cancer trial is a significant milestone, as it moves closer to potential clinical application. Ovarian clear cell carcinoma is a rare and aggressive form of ovarian cancer with limited treatment options, making the progress of LB-100 particularly noteworthy. The positive safety data in combination with immunotherapy suggests that LB-100 could become a backbone therapy for certain cancers.
In addition to its oncology pipeline, LIXTE is strengthening its position through its wholly owned subsidiary, Liora Technologies Europe Ltd., which is developing the LiGHT System, an electronically controlled proton therapy system for treating tumors. This technology is believed to provide significant advantages over currently available proton therapy systems. The strategic acquisition and growth of Liora Technologies reflect LIXTE's commitment to expanding its capabilities in cancer treatment development.
For more information on the company and its latest updates, visit the newsroom at https://ibn.fm/LIXT. Additional details about LIXTE can be found at www.lixte.com, and information on Liora Technologies is available at www.lioratechnologies.com.
